Department of Obstetrics and Gynaecology, Faculty of Veterinary Medicine, Istanbul University, Istanbul, Turkey.
Theriogenology. 2012 Feb;77(3):662-74. doi: 10.1016/j.theriogenology.2011.07.046. Epub 2011 Oct 19.
The aim of the present study was to investigate the safety and efficacy of deslorelin, a GnRH agonist, implants in suppressing estrus behavior and matings in a controlled ambient environment in feline queens in the presence of a tomcat. Local and utero-ovarian side effects of deslorelin implants were also investigated. The queens were housed in groups and assigned to one of three treatments: group 1 received 9.5 mg deslorelin implants (N = 14), group 2 received 5 mg megestrol acetate tablets and 9.5 mg deslorelin implants (N = 7), and group 3 were given placebo implants (N = 7). All implants were placed subcutaneously cranial to the interscapular region under xylazine hydrochloride sedation. Ovarian activity was monitored by fecal estradiol (E(2)) analyses. The animals were observed daily and checked individually at three-day intervals for behavioral signs of estrus. After 18.5 mo of trial, queens were ovariohysterectomized, and ovaries and uteri were weighed and evaluated histologically. E(2) levels were significantly lower in group 1 and 2 than in group 3 with an average of 128.48 ± 19.97 ng/g, 90.44 ± 7.16 ng/g and 283.26 ± 39.21 ng/g, respectively, excepting the first week of treatment. After inserting implants an initial estrus-like increase in fecal E(2) concentrations occurred in all treated queens except one female in group 2. Ovarian and uterine weights were significantly different among the groups (P < 0.01), and were lowest in groups 1 and 2. Primordial and primary follicle numbers were significantly higher in groups 1 and 2 than in group 3 (P < 0.001). Endometrial gland, antral follicle, and corpus luteum (CL) numbers were highest in group 3 (P < 0.01, 0.001, and 0.001, respectively) compared with groups 1 and 2. Deslorelin implants successfully suppressed estrus behavior and E(2) secretion in queens for 18.5 mo of the study period. Further investigations are needed to demonstrate the effects of GnRH agonists on ovarian interstitial tissue.
本研究旨在探讨 GnRH 激动剂地洛瑞林（deslorelin）埋植剂在有公猫存在的情况下，在控制的环境中抑制母猫发情行为和交配的安全性和有效性。还研究了地洛瑞林埋植剂的局部和子宫卵巢副作用。将母猫分组并分配到以下三种处理之一：第 1 组接受 9.5 mg 地洛瑞林埋植剂（N = 14），第 2 组接受 5 mg 甲孕酮醋酸酯片和 9.5 mg 地洛瑞林埋植剂（N = 7），第 3 组接受安慰剂埋植剂（N = 7）。所有埋植剂均在肩胛间区域皮下用盐酸二甲苯胺噻嗪镇静下植入。通过粪便雌二醇（E(2)）分析监测卵巢活动。每天观察动物，并每隔三天对发情行为进行个体检查。经过 18.5 个月的试验后，对母猫进行卵巢子宫切除术，并称重卵巢和子宫并进行组织学评估。第 1 组和第 2 组的 E(2)水平明显低于第 3 组，平均分别为 128.48 ± 19.97 ng/g、90.44 ± 7.16 ng/g 和 283.26 ± 39.21 ng/g，除了治疗的第一周。在植入埋植剂后，所有治疗的母猫除了第 2 组的一只母猫外，粪便 E(2)浓度最初都出现发情样增加。各组之间的卵巢和子宫重量存在显著差异（P < 0.01），第 1 组和第 2 组最低。第 1 组和第 2 组的原始和初级卵泡数量明显高于第 3 组（P < 0.001）。子宫内膜腺、窦卵泡和黄体（CL）数量在第 3 组最高（P < 0.01、0.001 和 0.001），与第 1 组和第 2 组相比。地洛瑞林埋植剂成功抑制了发情行为和 E(2)分泌，在研究期间持续了 18.5 个月。需要进一步研究以证明 GnRH 激动剂对卵巢间质组织的影响。
